Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 389

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 389
---
 CARA STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE ESPP PROPOSAL.

When you consider the recommendation of the Cara Board in favor of approval of the ESPP, you should keep in mind that certain of Cara’s directors and officers have interests in the ESPP that are different from, in addition to, or in conflict with, your interests as a stockholder, including, among other things, the existence of financial and personal interests, which may result in a conflict of interest on the part of such director(s) between what he, she or they may believe is in the best interests of Cara and its stockholders and what he, she or they may believe is best for himself or themselves in determining to recommend that stockholders vote for the proposals. In addition, Cara’s officers have interests in the Merger that may conflict with your interests as a stockholder. See the section titled “The Merger — Interests of Cara Directors and Executive Officers in the Merger” for a further discussion of these considerations.

<div align='center'>210</div>

Equity Compensation Plan Information The following table provides information as of December 31, 2024 with respect to the shares of Cara common stock that may be issued under Cara’s existing equity compensation plans.

| ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 ​                                                          
 Plan Category                                              | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |                       ​ 
                       ​ 
                       ​ 
 Number of securities to 
 be issued upon exercise 
 of outstanding options, 
     warrants and rights | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​                      
 ​                      
 ​                      
 Weighted average       
 exercise price of      
 outstanding options,   
 warrants and rights(2) |     ​ 
     ​ 
     ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |                       ​ 
    Number of securities 
 remaining available for 
   future issuance under 
     equity compensation 
        plans (excluding 
           securities in 
        first column)(3) | ​    
 ​    
 ​    
 ​    
 ​    
 ​    
 ​    
 ​    |
|:-----------------------------------------------------------|:--|------------------------:|:--|:-----------------------|------:|:--|------------------------:|:-----|
| Equity compensation plans approved by security holders(1)  | ​ |                 420,373 | ​ | $                      | 86.35 | ​ |                 494,275 | ​